Here are the DEF 14A proxy statements from Ginkgo Bioworks Holdings WTS (DNABW) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow DNABW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DNABW filings page.
Ginkgo Bioworks Holdings, Inc. is asking shareholders to vote at its virtual 2026 annual meeting on June 11, 2026 at 8:00 a.m. Eastern Time. Shareholders will elect six directors, ratify Deloitte & Touche LLP as independent auditor for the year ending December 31, 2026, and cast an advisory vote on executive compensation, with the Board recommending “FOR” each item.
Holders of Class A common stock have one vote per share and holders of Class B common stock have ten votes per share, with 53,172,097 Class A shares and 8,963,350 Class B shares outstanding as of April 15, 2026. The proxy describes Ginkgo’s dual‑class governance, board committee structure, director pay (cash retainers plus stock options), and a pay program that emphasizes equity, including performance‑based restricted stock units for executives.
The filing also notes Deloitte audit fees of $4,042,215 for 2025 and summarizes the 2024 transition from EY to Deloitte, including previously reported material weaknesses in internal control over financial reporting. Shareholders may vote online, by phone, by mail, or during the virtual meeting.